Abstract 1753P
Background
RET fusions occur in 10-20% of pts with PTC. RET fusion testing enables identification of pts who may benefit from targeted treatments [tx]. This study described real-world RET fusion testing patterns for pts with PTC in France [FR], Germany [DE], Italy [IT], Spain [ES] and the UK.
Methods
Real-world data were drawn from the Adelphi Thyroid Cancer Disease Specific ProgrammeTM – a point-in-time survey conducted between July-December 2020 primarily with oncologists and endocrinologists in clinical practice. Physicians completed patient record forms for up to the next 4 consulting adult PTC pts. Study variables included demographics, diagnostic testing patterns, test results, timing of testing, test modalities, and samples used.
Results
A total of 207 physicians provided data on 713 pts with PTC (pt mean age 58 years, 61% female, mean time since diagnosis 3.7 years, 22% IT, 21% DE, 20% FR, 18% ES, 18% UK). Overall, 137 (19%) pts were tested for RET fusions (range: 30% FR to 10% ES); of these, 9 (7%) were positive. The mean (SD) time to get the results was 19.8 (12.4) days (range: 28 days FR to 11 days UK). Of those tested, 73 (53%) pts were tested to aid diagnosis, 37 (27%) were tested to monitor PTC, 27 (20%) for both diagnosis and monitoring. 27 (20%) pts had a known disease status at testing. Of these, 23 (85%) had locally advanced or metastatic disease when tested. Of the 57 (42%) of pts with known date of tx initiation, 46 (81%) were tested before tx initiation. Data were captured for 127 tests. Of these, 43% were conducted using next generation sequencing (range: 57% IT to 36% DE and ES), 24% using polymerase chain reaction (range: 29% FR to 13% IT), 15% using fluorescence in situ hybridisation (range: 23% DE to 0% UK). Most tests (64%) utilized tissue samples (range: 83% DE to 36% ES), and 23% blood samples (range: 52% ES to 11% DE).
Conclusions
With the emergence of selective RET inhibitors, there is an opportunity to improve treatment outcomes by increasing testing rates for RET fusions in pts with PTC to inform more nuanced tx decisions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Adelphi Group.
Funding
Adelphi Group.
Disclosure
M. Kostikas: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. U. Kiiskinen: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. T. Puri: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. M. Jen: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. R. Williams: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. A. Rider: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. L.M. Hess: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company.